Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288493 · ClinicalTrials.gov registry record · Phase 1
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
A Phase 1 study, sponsored by Poseida Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT03288493 is a Phase 1 study that was terminated before completion, run by Poseida Therapeutics. The registered enrollment target is 105 participants.
The verdict
NCT03288493, a Phase 1 study, was terminated before completion, sponsored by Poseida Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.
Interventions
- DRUG Rimiducid
- BIOLOGICAL P-BCMA-101 CAR-T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03288493
The ClinicalTrials.gov registry entry for NCT03288493 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Poseida Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimiducid is the first listed.
NCT03288493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03288493 about?
NCT03288493 is a clinical study titled "P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)". Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. ...
What is the current status of trial NCT03288493?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2017-09-20. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03288493?
The interventions under investigation include: Rimiducid (DRUG), P-BCMA-101 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03288493?
This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.